TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in

Berlin, Germany Berlin ( ; ) is the capital and largest city of Germany, by both area and population. With 3.7 million inhabitants, it has the highest population within its city limits of any city in the European Union. The city is also one of the states of ...

which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa). TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from ''Spiegel'', the German word for "mirror." The L-RNA are resistant to the natural RNA

nuclease In biochemistry, a nuclease (also archaically known as nucleodepolymerase or polynucleotidase) is an enzyme capable of cleaving the phosphodiester bonds that link nucleotides together to form nucleic acids. Nucleases variously affect single and ...

enzymes.

Products

Some Spiegelmer candidates were in clinical trials. A Spiegelmer (NOX-A12, olaptesed pegol) was under development as a combination therapy for a number of cancer indications. NOX-A12 targets

CXCL12 The stromal cell-derived factor 1 (SDF-1), also known as C-X-C motif chemokine 12 (CXCL12), is a chemokine protein that in humans is encoded by the ''CXCL12'' gene on chromosome 10. It is ubiquitously expressed in many tissues and cell types. St ...

(C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA. A different Spiegelmer (NOX-E36, emapticap pegol) was tested for the treatment of progressive

diabetic nephropathy Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function occurring in those with diabetes mellitus. Diabetic nephropathy is the leading cause of chronic kidney disease (CKD) and end-stage renal disease ...

. Favorable results were reported in June 2014 in a company press release. NOX-E36 targets

MCP-1 The chemokine (C-C motif) ligand 2 (CCL2) is also referred to as monocyte chemoattractant protein 1 (MCP1) and small inducible cytokine A2. CCL2 is a small cytokine that belongs to the CC chemokine family. CCL2 tightly regulates cellular mechan ...

, also called

CCL2 The chemokine (C-C motif) ligand 2 (CCL2) is also referred to as monocyte chemoattractant protein 1 (MCP1) and small inducible cytokine A2. CCL2 is a small cytokine that belongs to the CC chemokine family. CCL2 tightly regulates cellular mecha ...

. A third Spiegelmer (NOX-H94, lexaptepid pegol) was in a clinical trial for the treatment of

anemia Anemia (also spelt anaemia in British English) is a blood disorder in which the blood has a reduced ability to carry oxygen. This can be due to a lower than normal number of red blood cells, a reduction in the amount of hemoglobin availabl ...

of chronic disease.{{cite journal , vauthors=Schwoebel F, etal , title=The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys , journal=Blood , volume=121 , issue=12 , pages=2311–5 , date=March 2013 , pmid=23349391 , doi= 10.1182/blood-2012-09-456756, pmc=3606066

References

Biotechnology companies of Germany Pharmaceutical companies of Germany German brands Pharmaceutical companies established in 1997 Biotechnology companies established in 1997 German companies established in 1997 Medical and health organisations based in Berlin